Warning: The NCBI web site requires JavaScript to function. more...
Predicting Global Fund grant disbursements for procurement of artemisinin-based combination therapies.
Cohen JM, Singh I, O'Brien ME.
Malar J. 2008 Oct 2;7:200.
Related citations
Artemisinin-based combination therapies (ACTs): best hope for malaria treatment but inaccessible to the needy!
Mutabingwa TK.
Acta Trop. 2005 Sep;95(3):305-15. Review.
Absorptive capacity and disbursements by the Global Fund to Fight AIDS, Tuberculosis and Malaria: analysis of grant implementation.
Lu C, Michaud CM, Khan K, Murray CJ.
Lancet. 2006 Aug 5;368(9534):483-8.
A situational analysis of pharmacovigilance plans in the Global Fund Malaria and U.S. President's Malaria Initiative proposals.
Stergachis A, Bartlein RJ, Dodoo A, Nwokike J, Kachur SP.
Malar J. 2010 May 30;9:148.
The quest for universal access to effective malaria treatment: how can the AMFm contribute?
Matowe L, Adeyi O.
Malar J. 2010 Oct 8;9:274.
Estimating antimalarial drugs consumption in Africa before the switch to artemisinin-based combination therapies (ACTs).
Kindermans JM, Vandenbergh D, Vreeke E, Olliaro P, D'Altilia JP.
Malar J. 2007 Jul 10;6:91.
The challenges of changing national malaria drug policy to artemisinin-based combinations in Kenya.
Amin AA, Zurovac D, Kangwana BB, Greenfield J, Otieno DN, Akhwale WS, Snow RW.
Malar J. 2007 May 29;6:72.
The Global Fund and effective malaria treatment.
Lidén J, Nantulya VM.
Lancet. 2004 Apr 24;363(9418):1396. No abstract available.
Anti-malarial market and policy surveys in sub-Saharan Africa.
Diap G, Amuasi J, Boakye I, Sevcsik AM, Pecoul B.
Malar J. 2010 Apr 23;9 Suppl 1:S1.
Access to artemisinin combination therapy for malaria in remote areas of Cambodia.
Yeung S, Van Damme W, Socheat D, White NJ, Mills A.
Malar J. 2008 May 29;7:96.
[Control of malaria: market for artemisinin and its derivatives].
Pilloy J.
Med Trop (Mars). 2006 Dec;66(6):554-7. French.
Affordable medicines facility for malaria.
Bate R, Hess K.
Lancet Infect Dis. 2009 Jul;9(7):396-7. No abstract available.
Cost of increasing access to artemisinin combination therapy: the Cambodian experience.
Malar J. 2008 May 20;7:84.
Willingness and ability to pay for artemisinin-based combination therapy in rural Tanzania.
Saulo EC, Forsberg BC, Premji Z, Montgomery SM, Björkman A.
Malar J. 2008 Oct 31;7:227.
Spread of anti-malarial drug resistance: mathematical model with implications for ACT drug policies.
Pongtavornpinyo W, Yeung S, Hastings IM, Dondorp AM, Day NP, White NJ.
Malar J. 2008 Nov 2;7:229.
Ensuring sustained ACT production and reliable artemisinin supply.
Kindermans JM, Pilloy J, Olliaro P, Gomes M.
Malar J. 2007 Sep 15;6:125.
A major transition in malaria treatment: the adoption and deployment of artemisinin-based combination therapies.
Bosman A, Mendis KN.
Am J Trop Med Hyg. 2007 Dec;77(6 Suppl):193-7. Review.
Pattern of drug utilization for treatment of uncomplicated malaria in urban Ghana following national treatment policy change to artemisinin-combination therapy.
Dodoo AN, Fogg C, Asiimwe A, Nartey ET, Kodua A, Tenkorang O, Ofori-Adjei D.
Malar J. 2009 Jan 5;8:2.
Malaria overdiagnosis and burden of malaria misdiagnosis in the suburbs of central Sudan: special emphasis on artemisinin-based combination therapy era.
A-Elgayoum SM, El-Feki Ael-K, Mahgoub BA, El-Rayah el-A, Giha HA.
Diagn Microbiol Infect Dis. 2009 May;64(1):20-6.
Deployment of ACT antimalarials for treatment of malaria: challenges and opportunities.
Whitty CJ, Chandler C, Ansah E, Leslie T, Staedke SG.
Malar J. 2008 Dec 11;7 Suppl 1:S7. Review.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on